Skip to main content
SpringerLink
Log in

Effect of Atorvastatin on Serum Para-Oxonase-1 and C-Reactive Protein in Wistar Rats

  • Original Research Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

Statins have been widely used in the treatment of hypercholesterolemia and atherosclerotic disease. Atherosclerosis is an ongoing inflammatory response which is involved in mediating all stages of this multifactorial disease. The present study focuses on the long term effect of atorvastatin on the anti-atherogenic and anti-inflammatory properties with reference to para-oxonase and C-reactive protein levels in rats. Thirty six Wistar albino rats obtained from the central animal house were divided into 6 groups with 6 rats in each group. Group I and IV served as the control for male and female rats respectively. Group II and V comprised of male and female rats that received low dose of atorvastatin (10 mg/kg body weight). Group III and VI comprised of male and female rats that received high dose of atorvastatin (40 mg/kg body weight) for period of 45 days. Blood was collected by cardiac puncture. The plasma was analysed for total cholesterol, HDL cholesterol, C-reactive protein (CRP) and Paraoxonase-1, both basal Paraoxonase (BPON) & Salt stimulated Paraoxonase (SPON) by standard procedures. Results of the present study showed a reduction in TC and increase in HDL-C in both groups of rats receiving low and high dose of Atorvastatin. Both male and female rats responded similarly. The levels of CRP decreased in the male rats receiving either low or high dose of atorvastatin. Activity of SPON and BPON was increased only in the group receiving high dose of atorvastatin in both male and female rats.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–43.

    Article  CAS  PubMed  Google Scholar 

  2. Ferretti G, Bacchetti T, Moroni C, Savino S, Liuzzi A, Balzola F. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab. 2005;90:1728–33.

    Article  CAS  PubMed  Google Scholar 

  3. Aviram M, Rosenbalt M, Biasgaier CH, Newton RS, Primo-Parmo SL. Paraoxonase inhibits high density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paroxonase. Clin Invest. 1998;101:1581–91.

    Article  CAS  Google Scholar 

  4. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation. 2002;106:2884–7.

    Article  CAS  PubMed  Google Scholar 

  5. Durrington PN, Mackness B, Mcknesss MI. Paraoxanase and atherosclerosis. Atheroscler Thromb Vasc Biol. 2011;21:473–80.

    Article  Google Scholar 

  6. Aronow WS. Hypercholesterolemia: the evidence supports use of statins. Geriatrics. 2003;58(8):18–20.

    PubMed  Google Scholar 

  7. Aronow WS. Cholesterol: rationale for lipid-lowering in older patients with or without CAD. Geriatrics. 2001;56(9):22–5.

    CAS  PubMed  Google Scholar 

  8. Delbosc S, Cristol J-P, Descomps B, Mimran A, Jover B. Hypertension, simvastatin prevents angiotensin II—induced cardiac alteration and oxidative stress. Hypertension. 2002;40:142–7.

    Article  CAS  PubMed  Google Scholar 

  9. Corti R, Fayad ZA, Fuster V, Worthley SG, Helft G, Smith D. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high resolution, noninvasive magnetic resonance imaging. Circulation. 2001;104:249–52.

    Article  CAS  PubMed  Google Scholar 

  10. Bruckert E, Hayem G, Dejager S. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403–14.

    Article  CAS  PubMed  Google Scholar 

  11. Sattar N, Preiss D, Murray H, Welsh P. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.

    Article  CAS  PubMed  Google Scholar 

  12. Ridker PM, Hennekens CH, Buring JE. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in Women. N Engl J Med. 2000;342:836–43.

    Article  CAS  PubMed  Google Scholar 

  13. Meiattini F, Prencipe L, Bardelli F, Giannini G, Tarli P. The 4-hydroxybenzoate/4-aminophenazone Chromogenic system used in the enzymatic determination of serum cholesterol. Clin Chem. 1978;4:2161–5.

    Google Scholar 

  14. Burstein M, Schonick HP, Morfin R. Cholesterol in high density lipoprotein using magnesium and phosphotungstic acid. J Lipid Res. 1978;19:583.

    Google Scholar 

  15. Rifal N, Tracy RP, Ridker PM. Clinical efficacy of an automated high sensitivity C-reactive protein. Clin Chem. 1999;45(12):2136–41.

    Google Scholar 

  16. Gan KN, Smolen A, Eckernon HW, La Du BN. Purification of human serum paraoxonase/arylesterase. Evidence for one ester catalyzing both activities. Drug Metlab Dispos. 1991;19:100–6.

    CAS  Google Scholar 

  17. Adekunle AS, Bukoye OE. Assessment of anti-inflamatory activity of statin. Int J Pharm Pharm Sci. 2013;5(3):203–5.

    Google Scholar 

  18. Masatoshi F, Tatsuya M, Masaki I, Mayu T, Akiko I, Miwa K. Dose dependency in pleiotropic effects of atorvastatin. Int J Anquiol. 2007;16(3):89–91.

    Google Scholar 

  19. Rosenson RS, Koenig W. Utility of Inflammatory markers in the management of Coronary artery disease. Am J Cardiol. 2003;92:10i–8i.

    Article  PubMed  Google Scholar 

  20. Tekin A, Tekin G. Effects of atorvastatin on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically proven coronary artery disease. Am J Cardiol. 2004;94:206–9.

    Article  CAS  PubMed  Google Scholar 

  21. Aviram M, Sorenson R. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its Paraoxonase activities: selective active of human paraoxonase alloenzyme Q and R. Arterioscler Thromb Vasc Biol. 1998;10:1617–24.

    Article  Google Scholar 

  22. Mackness MI, Mackness B, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoprotein. Curr Opin Lipidol. 1996;7:69–76.

    Article  CAS  PubMed  Google Scholar 

  23. Mackness MI, Hennuyer M, Durrington PN. Paraoxonase activity is reduced by a pro atherosclerotic diet in rabbits. Biochem Biophys Res Commun. 2000;269:232–6.

    Article  CAS  PubMed  Google Scholar 

  24. Sutherland WHF, Walker RJ, de Jong SA, van Rij AM, Phillips V, Walker HL. Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. Arterioscler Thromb Vasc Biol. 1999;19:1340–7.

    Article  CAS  PubMed  Google Scholar 

  25. Van der Gaag MS, van Tol A, Scheek LM, James RW, Urgert R, Schaafsma G, et al. Daily moderate alcohol consumption increases serum paraoxonase activity: a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis. 1999;147:405–10.

    Article  PubMed  Google Scholar 

  26. Van Lenten BJ, Hama SY, De Beer FC, Stafforini DM, McIntyre TM, Prescott SM, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. J Clin Invest. 1995;96:2758–67.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Feingold KR, Memon RA, Moser AH, Grunfeld C. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis. 1998;139:307–15.

    Article  CAS  PubMed  Google Scholar 

  28. Hedrick CC, Hassan K, Hough GP, Yoo J, Simzar S, Quinto CR. Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism. Arterioscler Thromb Vasc Biol. 2000;20:1946–52.

    Article  CAS  PubMed  Google Scholar 

  29. Aviram M, Rosenblat M, Bisgaier CL, Newton RS. Atorvastatin and gemfibrozil metabolites, but not the parent drugs are potent antioxidant against lipoprotein oxidation. Atherosclerosis. 1998;138:271–80.

    Article  CAS  PubMed  Google Scholar 

  30. Paragh G, Balogh Z, Seres I, Harangi M, Boda J, Kovacs P. Effect of gemfibrozil on HDL-associated serum paraoxonase activity and lipoprotein profile in patients with hyperlipidaemia. Clin Drug Invest. 2000;19:277–82.

    Article  CAS  Google Scholar 

  31. Zhao Y, Ma Y, Fang Y, Liu L, Wu S, Fu D. Association between PON1 activity and coronary heart disease risk: a meta-analysis based on 43 studies. Mol Genet Metab. 2012;105:141–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry, Kasturba Medical College, Mangaluru, Manipal Academy of Higher Education, Manipal, Karnataka, India

    Aradhana Marathe, K. Ashwin Shenoy, K. Ashok Prabhu & M. Nandini

  2. Department of Physiology, Kasturba Medical College, Mangaluru, Manipal Academy of Higher Education, Manipal, Karnataka, India

    B. Ganaraja

Authors
  1. Aradhana Marathe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Ganaraja
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. Ashwin Shenoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Ashok Prabhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Nandini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Nandini.

Ethics declarations

Conflict of interest

All authors declare that they have no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Marathe, A., Ganaraja, B., Ashwin Shenoy, K. et al. Effect of Atorvastatin on Serum Para-Oxonase-1 and C-Reactive Protein in Wistar Rats. Ind J Clin Biochem 34, 312–317 (2019). https://doi.org/10.1007/s12291-018-0742-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-018-0742-1

Keywords

Search

Navigation